

(12) STANDARD PATENT
(19) AUSTRALIAN PATENT OFFICE

(11) Application No. **AU 2017344059 B2**

(54) Title
Fusion protein between short form rod-derived cone viability factor and a hydrophilic peptide

(51) International Patent Classification(s)
C07K 14/47 (2006.01) **C12N 15/86** (2006.01)

(21) Application No: **2017344059** (22) Date of Filing: **2017.10.11**

(87) WIPO No: **WO18/071465**

(30) Priority Data

(31)	Number	(32)	Date	(33)	Country
	62/406,552		2016.10.11		US

(43) Publication Date: **2018.04.19**

(44) Accepted Journal Date: **2021.12.23**

(71) Applicant(s)
Wellstat Ophthalmics Corporation

(72) Inventor(s)
Luo, Tianci;Zhang, Jun

(74) Agent / Attorney
FB Rice Pty Ltd, Level 14 90 Collins Street, Melbourne, VIC, 3000, AU

(56) Related Art
LEVEILLARD THIERRY ET AL, "Identification and characterization of rod-derived cone viability factor", NATURE GENETICS, NATURE PUBLISHING GROUP, NEW YORK, US, (2004-07-01), vol. 36, no. 7, doi:10.1038/NG1386, ISSN 1061-4036, pages 755 - 759
WO 02/081513 A2
WO 2009/146183 A1
US 2005/0054570 A1
US 2004/0063635 A1



(51) International Patent Classification:

C07K 14/47 (2006.01) C12N 15/86 (2006.01)

TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2017/056030

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(22) International Filing Date:

11 October 2017 (11.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/406,552 11 October 2016 (11.10.2016) US

(71) Applicant: **WELLSTAT OPHTHALMICS CORPORATION** [US/US]; 14200 Shady Grove Road, Suite 600, Rockville, MD 20850 (US).

(72) Inventors: **LUO, Tianci**; 6512 Tipperary Court, Clarksville, MD 21029 (US). **ZHANG, Jun**; 6109 Swift Current Way, Clarksville, MD 21029 (US).

(74) Agent: **KREISLER, Lewis J.**; Wellstat Management Company, LLC, 14200 Shady Grove Road, Suite 600, Rockville, MD 20850 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE

(57) Abstract: A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced *in vitro* by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.



FUSION PROTEIN BETWEEN SHORT FORM ROD-DERIVED CONE VIABILITY FACTOR AND A HYDROPHILIC PEPTIDE

5

REFERENCE TO SEQUENCE LISTING

The Sequence Listing filed electronically in the form of an Annex C/ST.25 text file and bearing file reference WOC-019PCT is a part of the disclosure.

BACKGROUND OF THE INVENTION

10 RdCVF is a thioredoxin-like protein specifically expressed by rod photoreceptor cells in the retina (Léveillard *et al.* (2004) Nature Genetics 36:755-759 and the supplemental information). Two different RdCVF genes are found in humans and they are designated RdCVF1 and RdCVF2. Both RdCVF genes encode two products via alternative splicing: a full length protein and a C-terminal post-transcriptionally truncated
15 protein, known as RdCVF-long (RdCVFL) and RdCVF-short (RdCVFS), respectively. The nucleoredoxin-like-1 gene (Nxn1) encodes a long and a short form RdCVF by alternative splicing mechanism. Nxn1 knockout results in progressive loss of rods and cones in mice, suggesting at the genetic level this gene is fundamentally essential for survival of photoreceptor cells and maintaining proper retina physiology and function.

20 RdCVFS is described as a secreted trophic factor for promoting cone survival, and RdCVFL as a redox-active enzyme that interacts with intracellular proteins (Léveillard *et al.* (2010) Sci Transl Med. 2(26): 26ps16). For example, tau is described as a binding partner for RdCVF-L and tau is exclusively intracellular (Fridlich *et al.* (2009) Molecular & Cellular Proteomics 8(6):1206-18).

25 Individuals suffering from some retinal dystrophies were found to have lower levels of RdCVF protein in their eyes than did individuals without retinal dystrophies (PCT Publication WO 02/081513).

It has been demonstrated that different forms of RdCVF protein can promote cone photoreceptor cell survival *in vitro* and *in vivo*. For example, intraocular injections of the
30 short form of human RdCVF1 (RdCVF1S) protein not only rescued cone cells from

degeneration but also preserved their function in animal models of inherited retinal degeneration (Yang *et al.* (2009) Mol Therapy 17:787-795). However, demonstration of the *in vivo* cone cell protective effect of this protein required multiple intraocular injections.

5 Retinitis pigmentosa (RP) is retinal degenerative eye disease characterized by progressive rod degeneration followed by secondary loss of cones. RP is the leading cause of inherited blindness, affecting approximately 100,000 patients with 2,000 new cases per year in US alone. RP affects all ethnicities. More than 1.5 million people are affected by RP worldwide. Unfortunately for the patients, there is no effective therapy or
10 approved therapy for RP. Therefore, RP remains an urgent unmet medical need.

 Since RP is a chronic retinal degenerative disease with a clinical course over years to decades, gene therapy could be ideal for RP indication by expressing RdCVF in the retina constitutively. For acute emergency indications such as retinal detachment, protein therapy could be beneficial. That is to use recombinant RdCVF protein to protect
15 photoreceptors from dying before the retina could be re-connected to the back of the eye, i.e., retinal pigment epithelium and choroid layers. Unfortunately, scientists in the field have encountered considerable difficulties to effectively express and secrete RdCVF protein, especially the short form RdCVF. See, for example, U.S. Patent Publication No. 20110034546, paragraph [0004].

20 SUMMARY OF THE INVENTION

 This invention provides a fusion protein comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence,
25 and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved in the endoplasmic reticulum, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide.

30 Therefore this invention also provides a fusion protein comprising a second peptide sequence and a third peptide sequence C-terminal to the second peptide sequence;

wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. This invention also provides nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and
5 uses of the fusion protein, nucleic acid, and expression vector. This invention also provides a method for producing the fusion protein comprising culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.

10 BRIEF DESCRIPTION OF THE FIGURES

Figure 1A shows amino acid sequence of human short form rod-derived cone viability factor. The amino acid composition for the human short RdCVF is highly hydrophobic. 38.5% of amino acids are hydrophobic in short RdCVF. Underlined amino
15 acids are hydrophobic.

Figure 1B shows amino acid sequence of human long form rod-derived cone viability factor. 25% of amino acids are hydrophobic at the C-terminus of long RdCVF (Underlined amino acids are hydrophobic at the C-terminus of the long form RdCVF)
20

Figure 2. Fusion protein between short RdCVF and hydrophilic domain. Figure 2 shows schematic representations of two human short RdCVF fusion proteins. Human short RdCVF is fused with a hydrophilic domain at its N-terminus or C-terminus. The fusion protein has a signal peptide to facilitate secretion from cells.
25

Figure 3. Expression and secretion of novel fusion proteins between human albumin and human short RdCVF.

Figure 3 shows a Western blot analysis of human short RdCVF and human albumin fusion proteins.

30 Lane 1: 30 μ L of cell culture medium from human 293 cells transduced with AAV-GFP, an AAV vector encoding GFP as a control;

Lane 2: 30 μ L of cell culture medium from human 293 cells transduced with AAV-ALB-RdCVFS, an AAV vector encoding the short form human RdCVF fused with human albumin at the N-terminus of short RdCVF;

Lane 3: 30 μ L of cell culture medium from human 293 cells transduced with AAV-RdCVFS-ALB, an AAV vector encoding the short form human RdCVF fused with human albumin at the C-terminus of short RdCVF.

The numbers on the left indicate molecular weight marker in KDa.

BRIEF DESCRIPTION OF THE SEQUENCE LISTING

10

SEQ ID NO: 1. Amino acid sequence of a fusion protein between human albumin and short RdCVF with human albumin at the N-terminus of the fusion protein (ALB-RdCVFS)

15 SEQ ID NO: 2. Nucleotide Sequence Encoding the Human Short RdCVF Fused with Human Albumin at N-terminus (ALB-RdCVFS)

SEQ ID NO: 3. Amino acid sequence of a fusion protein between human albumin and short RdCVF with human albumin at the C-terminus of the fusion protein (RdCVFS-ALB). There is a four amino acid spacer between RdCVFS and the human albumin. The first 21 amino acids from the N-terminus are signal sequence from mouse Igk. There is a 14 amino acid spacer (linker) between the signal sequence and RdCVFS.

25 SEQ ID NO:4. Nucleotide Sequence Encoding the Human Short RdCVF Fused with Human Albumin at C-terminus (RdCVFS-ALB)

SEQ ID NO: 5. Amino acid sequence of human short form rod-derived cone viability factor.

30 SEQ ID NO:6. Amino acid sequence of human long form rod-derived cone viability factor.

DETAILED DESCRIPTION OF THE INVENTION

Without wishing to be bound by theory, the difficulty to express and secrete the short form RdCVF could potentially be due to its high hydrophobic amino acid composition. Careful analysis of the amino acid composition of both the short form and the long form of human RdCVF proteins revealed that the short form RdCVF protein is extremely hydrophobic (Figures 1A and 1B). Forty two amino acids out of 109 (38.5%) are hydrophobic amino acids in short RdCVF. There is one stretch of six hydrophobic amino acids, one stretch of four hydrophobic amino acid, and two stretches of three hydrophobic amino acids each. It is highly likely that the high percentage of hydrophobic amino acid composition makes the short RdCVF very difficult to be expressed and secreted efficiently *in vitro* and *in vivo* from mammalian cells as it is more likely to stick to lipid membranes via hydrophobic-hydrophobic interactions. Interestingly, although the N-terminal 109 amino acids in the long form RdCVF are identical to the entire short RdCVF, the C-terminal 103 amino acids of the long RdCVF is not hydrophobic with only 25% of amino acids being hydrophobic (26 out of 103). The longest hydrophobic amino acids stretch in this C-terminus of the long RdCVF is only four amino acids long. There is no stretch of three hydrophobic amino acids. The relatively hydrophilic nature in the C-terminus of long RdCVF may play an important role in reducing the overall hydrophobicity of the long RdCVF.

In one embodiment of the fusion protein of this invention, the second peptide sequence is an RdCVF-short peptide sequence and the third peptide sequence is a hydrophilic peptide sequence. In another embodiment the second peptide sequence is a hydrophilic peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence.

There should be an N-terminal signal peptide sequence that will facilitate the secretion of the fusion protein out of the cells that express this fusion protein. Any signal peptide that enables the secretion of a protein from mammalian cells can be utilized. In further embodiments, the signal peptide sequence is selected from the group consisting of an Igk signal peptide sequence and an albumin signal peptide sequence. In more specific

embodiments the IgK signal peptide sequence is a mouse IgK signal peptide sequence and the albumin signal peptide sequence is a human albumin signal peptide sequence.

In a preferred embodiment of this invention the RdCVF-short peptide sequence is a human RdCVF-short peptide sequence. Examples of suitable RdCVF-short peptide sequences include an RdCVF1-short peptide sequence, an RdCVF2-short peptide sequence, and an RdCVF-short peptide sequence that differs from a corresponding wild-type sequence, for example by one or more conservative amino acid substitutions.

In accordance with this invention any hydrophilic peptide sequence can be utilized provided that lowers the hydrophobicity index of the fusion protein compared to the RdCVF-short peptide sequence without the hydrophilic peptide sequence. In one embodiment of this invention the fusion protein, including any signal peptide sequence if present, has a hydrophobicity index less than negative 0.20, more preferably less than negative 0.30.

Preferably the hydrophilic peptide sequence is not immunogenic in humans, does not present any other negative effect on human retinal physiology or normal retinal function, and does not affect short RdCVF's biological function. The hydrophilic peptide sequence can be a hydrophilic protein, a hydrophilic protein domain, a hydrophilic oligopeptide, or a hydrophilic polypeptide. More than one hydrophilic domain can be the candidate as the hydrophilic fusion partner with short RdCVF. In one embodiment of this invention the hydrophilic peptide sequence is an albumin, for example a human albumin.

In accordance with the fusion protein of this invention there can optionally be a spacer of one or more amino acids between the first peptide sequence and the second peptide sequence, between the second peptide sequence and the third peptide sequence, or both. In one embodiment of this invention there is no spacer between the first peptide sequence and the second peptide sequence, or in other words the first peptide sequence is covalently bonded to the second peptide sequence by a single peptide bond. In another embodiment there is a spacer between the first peptide sequence and the second peptide sequence. In another embodiment of this invention there is no spacer between the second peptide sequence and the third peptide sequence, or in other words the second peptide sequence is covalently bonded to the third peptide sequence by a single peptide bond. In another embodiment there is a spacer between the second peptide sequence and the third

peptide sequence. There is in principle no limitation on the size of the spacers. In an embodiment of this invention the spacer between the first and second peptide sequence has two to fourteen amino acids. In another embodiment the spacer between the second and third peptide sequences has from two to fourteen amino acids, more specifically
5 between two and four amino acids.

One embodiment of the fusion protein coding sequence of this invention further comprises a polyadenylation signal C-terminal to the third peptide sequence coding sequence. The polyadenylation signal (Poly A) can be any Poly A.

In one embodiment of the fusion protein of this invention, the first peptide
10 sequence is a human albumin signal sequence, the second peptide sequence is a human albumin, and the third peptide sequence is an RdCVF-short sequence. In a more specific embodiment the fusion protein has the sequence (SEQ ID NO:1) or amino acids 25-717 of (SEQ ID NO:1). In another embodiment of the fusion protein of this invention the first peptide sequence is an Igk signal sequence, the second peptide sequence is an RdCVF-
15 short sequence, and the third peptide sequence is a human albumin. In a more specific embodiment the fusion protein has the sequence (SEQ ID NO:3) or amino acids 22-732 of (SEQ ID NO:3).

In an embodiment of the fusion protein of this invention, wherein one, two, or all of the signal peptide sequence, the RdCVF-short peptide sequence, and the hydrophilic
20 peptide sequence differs from a corresponding wild-type sequence. In a more specific embodiment the differences comprise one or more conservative amino acid substitutions. And in a still more specific embodiment the amino acid substitutions are limited one or more conservative amino acid substitutions.

The fusion protein in accordance with this invention can be glycosylated or not
25 glycosylated. Generally speaking, glycosylation is beneficial for a protein's stability and solubility. In one embodiment the fusion protein expressed in cells transduced by an expression vector in accordance with this invention is glycosylated and is glycosylated after secretion from the cells.

In an embodiment the nucleic acid of this invention is DNA. In another
30 embodiment the coding sequence for one, two, or all of the signal peptide sequence, the RdCVF-short peptide sequence and the hydrophilic peptide sequence is recoded

compared to a corresponding wild-type sequence. In a more specific embodiment the coding sequence for the RdCVF-short peptide sequence is recoded. The nucleic acid of this invention can optionally comprise one or more introns, either between the first and the second peptide sequences, between the second and third peptide sequences, or
5 elsewhere. In one embodiment of this invention the nucleic acid encodes a fusion protein having the sequence (SEQ ID NO:1), for example a nucleic acid having the sequence (SEQ ID NO:2). In another embodiment the nucleic acid encodes a fusion protein having the sequence (SEQ ID NO:3), for example a nucleic acid having the sequence (SEQ ID NO:4). Other nucleic acid sequences can readily be envisioned in view of the degeneracy
10 of the genetic code.

An embodiment of this invention is an expression vector comprising the nucleic acid described above operatively linked to a control sequence, for example a promoter. The promoter driving the RdCVFS fusion protein can be any promoter and is not limited to CMV promoter. When there is an intron between the promoter and the fusion protein
15 coding sequence, any suitable and conventional intron can be utilized. For example, β -globin intron is suitable.

In the experiments two fusion proteins were created by fusing human short RdCVF with a hydrophilic domain (See Figure 2 for schematic). One was human short RdCVF fused with human albumin at the N-terminus with an albumin signal peptide at
20 the N-terminus of the fusion protein (SEQ ID NO:1). The expression construct to express and secrete this fusion protein was engineered in the context of an AAV vector, designated rAAV-ALB-RdCVFS. This vector encoded a codon-optimized (recoded) human short RdCVF fused with human albumin at the N-terminus (SED ID NO:2). The fusion protein was named ALB-RdCVFS. A coding sequence for human albumin signal
25 peptide was also incorporated into the fusion protein expression construct upstream of the fusion protein coding sequence. The expression construct further contained a CMV promoter and an intron that linked to the fusion protein coding sequence. The expression construct further contained a polyadenylation signal at the C-terminus of the fusion protein coding sequence. The entire expression cassette was cloned into an AAV
30 expression plasmid and the plasmid was subjected to DNA sequencing to confirm the integrity of the expression construct.

The other exemplified fusion protein was human short RdCVF fused with human albumin at the C-terminus with a mouse Igk signal peptide at the N-terminus of the fusion protein (SEQ ID NO:3). The expression construct to express and secrete this fusion protein was engineered in the context of an AAV vector, designated rAAV-
 5 RdCVFS-ALB. This vector encoded a codon-optimized (recoded) human short RdCVF fused with human albumin at the C-terminus (SEQ ID NO:4). The fusion protein was named RdCVFS-ALB. A coding sequence for a modified mouse Igk signal peptide was also incorporated into the fusion protein expression construct upstream of the fusion protein coding sequence. The expression construct further contained a CMV promoter
 10 and an intron that linked to the fusion protein coding sequence. The expression construct further contained a polyadenylation signal at the C-terminus of the fusion protein coding sequence. The entire expression cassette was cloned into an AAV expression plasmid and the plasmid was subjected to DNA sequencing to confirm the integrity of the expression construct.

15 There are a total of 20 naturally-occurring amino acids. Some of them are hydrophobic and some of them are hydrophilic. The hydrophobicity index of an amino acid is a number representing the hydrophobic or hydrophilic properties of its sidechain. The larger the number is, the more hydrophobic the amino acid (Table 1). The most hydrophobic amino acids are isoleucine (4.5) and valine (4.2). The most hydrophilic ones
 20 are arginine (-4.5) and lysine (-3.9). Although a protein's hydrophobic or hydrophilic nature depends on what amino acids it is made of, as well as the secondary, tertiary and quaternary structure, the hydrophobicity index of a protein can have predictive value for a protein's hydrophobicity.

25 Table 1. Hydrophobicity Value of Amino Acids

Ala: 1.800

Arg: -4.500

30 Asn: -3.500

Asp: -3.500

Cys: 2.500

	Gln: -3.500
	Glu: -3.500
5	Gly: -0.400
	His: -3.200
	Ile: 4.500
10	Leu: 3.800
	Lys: -3.900
15	Met: 1.900
	Phe: 2.800
	Pro: -1.600
20	Ser: -0.800
	Thr: -0.700
25	Trp: -0.900
	Tyr: -1.300
	Val: 4.200
30	

The publicly-available GPMW program was used to calculate the hydrophobicity index for the short RdCVF, and the two short RdCVF and albumin fusion proteins. The hydrophobicity index for the native short form of human RdCVF (RdCVFS) is -0.12. After fusing the human albumin to the N-terminus of RdCVFS, the resulting fusion protein, ALB-RdCVFS had its hydrophobicity index reduced from -0.12 to -0.32 (including the signal peptide), a 266.7% reduction in hydrophobicity index. After fusing the human albumin to the C-terminus of RdCVFS, the resulting fusion protein, RdCVFS-ALB had its hydrophobicity index reduced from -0.12 to -0.33 (including the signal peptide), a 275% decrease in hydrophobicity index. The dramatic reduction in

hydrophobicity index may have contributed to efficient expression and secretion of the fusion proteins.

Furthermore, the fusion protein coding sequence has been cloned into an AAV-2 expression construct, the data included here clearly showed that this novel fusion protein was efficiently expressed as detected by Western blot with RdCVF specific antibodies (Figure 3). The fusion partner for the short RdCVF is not limited to human albumin. Any hydrophilic protein or hydrophilic protein domain or hydrophilic peptide could be used to create a fusion protein with short RdCVF to reduce the protein's hydrophobicity. A preferred hydrophilic domain is non-immunogenic to human.

The protein can be encoded and delivered by a gene therapy vector such as AAV (Adeno-associated Virus) vector, Lentiviral vector, synthetic vector, adenoviral vector, retroviral vector, naked DNA, nanoparticles, etc. Alternatively, the fusion protein can be delivered to the retina as a recombinant protein. The hydrophilic fusion domain should not present any negative effect on human retinal physiology or normal retinal function, and should not affect short RdCVF's biological function. Potentially, more than one hydrophilic domain can be the candidate as the hydrophilic fusion partner with short RdCVF. In the examples, human albumin was used as the hydrophilic domain to serve as a fusion partner for human short RdCVF.

This invention provides a pharmaceutical composition comprising: (i) a component selected from the group consisting of a fusion protein, nucleic acid, expression vector, or cell of this invention; and (ii) a pharmaceutically acceptable carrier.

This invention provides a method for treating a condition amenable to such treatment in a mammalian patient, the treatment comprising administering to the patient an effective amount of the protein, the nucleic acid, the vector, the cell, or the pharmaceutical composition described herein, thereby treating the condition in the patient. In embodiments of this invention the condition is selected from the group consisting of retinal dystrophy, Stargardt's disease, retinitis pigmentosa, dry age-related macular degeneration (dry AMD), geographic atrophy (advanced stage of dry AMD), wet age-related macular degeneration (wet AMD), glaucoma with or without ocular hypertension, diabetic retinopathy, Bardet-Biedel syndrome, Bassen-Kornzweig syndrome, Best disease, choroidema, gyrate atrophy, congenital amaurosis, refsun

syndrome, Usher syndrome, thyroid related eye disease, Grave's disease, a disease associated with retinal pigmented epithelial cells, anterior segment disease, lens disease/cataracts, an eye cup disorder, uveitis, Alzheimer's disease, Huntington's disease, Parkinson's disease, and an olfactory disease. Any conventional route of administration can be utilized, for example, injection to the eye, intravenous injection, or other systemic administration. In an embodiment of the method of this invention the condition is an ocular condition and the administration is selected from the group consisting of subretinal injection and intravitreal injection. In a more specific embodiment the patient is a human patient.

This invention provides a method of protecting ocular photoreceptor cells in a patient, comprising administering to the eye of the patient an effective amount of the fusion protein, nucleic acid, vector, cells, or pharmaceutical composition of this invention, thereby protecting the ocular photoreceptor cells in the patient. In a more specific embodiment the administration is selected from the group consisting of subretinal injection and intravitreal injection. In a more specific embodiment the patient is a human patient.

The invention is now described with reference to the following examples. These examples are provided for the purpose of illustration only and the invention should in no way be construed as being limited to these examples but rather should be construed to encompass any and all variations which become evident as a result of the teachings provided herein.

Whereas, particular embodiments of the invention have been described herein for purposes of description, it will be appreciated by those skilled in the art that numerous variations of the details may be made without departing from the invention as described in the appended claims.

All publications, patents and patent applications mentioned in this specification are herein incorporated by reference in their entirety into the specification to the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated herein by reference. Also incorporated by reference is any supplemental information that was published along with any of the

aforementioned publications, patents and patent applications. For example, some journal articles are published with supplemental information that is typically available online.

EXAMPLES

5 EXAMPLE 1: Generation of rAAV vectors encoding human short form rod-derived cone viability factor and albumin fusion proteins

Plasmid Cloning

The cDNA of the codon-optimized human short form of the RdCVF protein fused with human albumin at its N-terminus was synthesized by GENEART® (a fee-for-service
10 company) and cloned into the adeno-associated virus vector plasmid pAAV-MCS (Cell Biolabs, San Diego, CA), creating the plasmid pAAV-ALB-RdCVFS. The signal peptide from human albumin was also incorporated at the upstream of the RdCVF and albumin fusion protein coding sequence.

The pAAV-ALB-RdCVFS plasmid contains the following features between
15 AAV-ITRs:

CMV promoter — β -globin intron — Signal sequence-Albumin-short RdCVF —
Poly A

The resulting amino acid sequence for this RdCVF and albumin fusion protein is shown in SEQ ID NO: 1.

20 The cDNA of the codon-optimized human short form of the RdCVF protein fused with human albumin at its C-terminus was synthesized by GENEART® (a fee-for-service company) and cloned into the adeno-associated virus vector plasmid pAAV-MCS (Cell Biolabs, San Diego, CA), creating the plasmid pAAV-RdCVFS-ALB. This signal peptide from mouse Igk was also incorporated at the upstream of the RdCVF and
25 albumin fusion protein coding sequence.

The pAAV-RdCVFS-ALB plasmid contains the following features between AAV-ITRs:

CMV promoter — β -globin intron — Signal sequence- short RdCVF-Albumin — Poly A

The resulting amino acid sequence for this RdCVF and albumin fusion protein is shown in SEQ ID NO: 3.

5 Production and Purification of Recombinant AAV-ALB-RdCVFS and AAV-RdCVFS-ALB Vectors

Plasmids pAAV-ALB-RdCVFS or pAAV-RdCVFS-ALB, pHELPER (Cell BioLabs, Catalog No. 340202), and pRC2 (Cell BioLabs, Catalog No. 340201) were transformed into DH10B competent bacteria cells (Invitrogen, Catalog No. 18297-010) and scaled up using the Qiagen EndoFree Plasmid Maxi Kit or EndoFree Plasmid Mega Kit according to the manufacturer's instructions. The plasmid concentrations were determined using a Beckman DU-600 spectrophotometer. Each plasmid's identity was confirmed by restriction digests and DNA sequencing analysis.

To produce rAAV-ALB-RdCVFS or rAAV-RdCVFS-ALB vector, 293AAV cells (Cell BioLabs, Catalog No. AAV-100) were seeded at 4 million cells per 15 cm dish in cDMEM (DMEM supplemented with 10% FBS, 1% Glutamine, 1% non-essential amino acids, and 1% Penicillin/Streptomycin). The following day the medium was replaced with 25 mL fresh cDMEM. Two hours later the transfection was performed. Water (57.4 mL) was mixed with 1.3 mg pHELPER, 650 μ g pRC2, 650 μ g pAAV-ALB-RdCVFS or pAAV-RdCVFS-ALB, and 8.1 mL 2 M CaCl_2 (water/plasmid/ CaCl_2 mix). A 12.5 mL volume of 2xHBS (Lonza, Sku:RR07005) was transferred into each of five 50 mL conical tubes. While vortexing, 12.5 mL of the water/plasmid/ CaCl_2 mix was slowly added to each of the conical tubes containing 2xHBS. After a 5-minute incubation, 2.5 mL of the suspension was added to each cell culture dish containing the 293AAV cells.

The following day the medium was replaced with 25 mL new cDMEM medium per dish. Two days later the cells were harvested using a cell lifter and the cell/medium mix was transferred into 250 mL conical tubes. The samples were centrifuged at 3,000 rpm for 15 minutes at 4°C, the supernatant was discarded and the cell pellets resuspended in 110 mL DMEM. The resuspended cell samples were aliquoted (30 mL) into 50 mL

conical tubes and a freeze/thaw/freeze step was performed using ethanol/dry ice bath and 37°C water bath. The tubes were stored at -80°C until further process of the material. The same process was employed to produce rAAV-GFP control vector, substituting the plasmid pAAV-ALB-RdCVFS with the plasmid pAAV-GFP (Cell BioLabs Catalog No. AAV-400).

To purify the rAAV-ALB-RdCVFS vector, four 50 mL conical tubes containing the vector from the freeze/thaw/freeze step was thawed at 37°C in a water bath. Forty microliters of BENZONASE® (nuclease) (Sigma, Catalog No. E8263-25kU) was added to each tube which was then incubated at 37°C for 30 minutes. The tubes were centrifuged for 10 minutes at 3,000 rpm and the supernatants were transferred into a 500 mL bottle. Six milliliters of a 10% sodium deoxycholate solution (8.2 g in 82 mL water) was added. The sample was briefly mixed and incubated at 37°C for 30 minutes. The suspension was filtered using 5 µm filters. Subsequently, another filtration step using 0.8 µm filter was performed. A heparin agarose column (8 mL) (Sigma, Catalog No. H6508-25mL) was prepared and the column was equilibrated with 48 mL phosphate buffered saline (PBS) (Invitrogen, Catalog No. 10010-049). The filtered cell lysate was loaded onto the column and the column was washed with 40 mL washing buffer (20 mL 5 M NaCl, 980 mL PBS). The vector was eluted using 15 mL elution buffer (80 mL 5 M NaCl, 920 mL PBS) and collected in a new 50 mL conical tube.

The vector was concentrated by centrifugal filtration. An AMICON ULTRA-15 centrifugational filter unit (Millipore, Catalog No. UFC910024) was rinsed once with PBS and the eluted sample was added to the device. Centrifugation was performed in a Beckman Allegro 6KR centrifuge at 2,200 rpm, 22°C, until the sample was concentrated to a 1-2 mL volume. A 15 mL volume of PBS was added and the centrifugation was repeated until the sample volume was ≤ 1 mL. The purified vector was collected and the filter walls rinsed with 100 µL of PBS. The sample was mixed and 30 µL aliquots of the vector were stored at -80°C in 600 µL conical tubes until use.

This process was repeated to purify the rAAV-RdCVFS-ALB and rAAV-GFP vectors.

EXAMPLE 2: Expression and secretion of human short RdCVF and human albumin fusion proteins mediated by rAAV vectors

Western blot analysis using a 4-20% SDS-PAGE gel was used to detect RdCVF and albumin fusion protein expression using standard techniques. As a control, a 5 μ L volume of MAGICMARK™ XP Western Protein Standard (Invitrogen, Catalog No. LC5602) was added to the outer wells. 30 μ L of cell culture medium from each rAAV vector transduced human 293 cells mixed with protein sample buffer was added to each well. The gel was run at 200 V until the dye reached the bottom of the gel. Western blot analysis was performed with a VECTASTAIN® ABC-Amp Western blot analysis kit by Vector Laboratories, according to a modified version of the manufacturer's instructions. The SDS-PAGE was equilibrated in transfer buffer for 20 min and proteins separated by SDS-PAGE were transferred onto a nitrocellulose membrane using a Trans Blot Semi-Dry Transfer Cell at 20 V for 40 minutes. Once the transfer was completed, the membrane was blocked in 200 mL of 1x casein solution with gentle agitation on a rocker platform for at least two hours at room temperature (RT) or at 4°C over night. The membrane was incubated with 50 mL 1x casein solution containing rabbit anti-RdCVF protein specific antibody (primary antibody, generated by Covance (Denver, PA) diluted 1:2,000 with gentle agitation at 4°C overnight or 1 hour at room temperature. The membrane was washed with 30 mL of a 1x casein solution 4 times for 5 minutes each at RT with gentle agitation. The membrane was incubated with 30 mL of biotinylated goat anti-rabbit IgG (secondary antibody) diluted 1:10,000 in 1x casein solution for 1 hour at RT with gentle agitation. The membrane was washed in 30 mL of 1x casein solution 3 times for 5 minutes each at RT with gentle agitation. The membrane was incubated for 45 minutes in Vectastain ABC-Amp in 50 mL of 1x casein containing 100 μ L of Reagent A and 100 μ L of Reagent B. The membrane was washed in 30 mL of 1X casein solution 3 times for 5 minutes each at RT with gentle agitation.

The membrane was incubated in Tris, pH 9.5. The chemiluminescent signal was acquired using 6 mL of DUOLOX Substrate (Vector Laboratories, Catalog No. SK 6605) and exposing the membrane to KODAK BIOMAX MS X-ray film (Kodak Carestream Health, Catalog No. 8572786) in a film cassette for 10 seconds to 5 minutes followed by

development of the film using KODAK Developer solution (Kodak GBX, Catalog No. 1900984) and KODAK Fixer solution.

As shown in Figure 3, cell culture medium from both rAAV-ALB-RdCVFS and rAAV-RdCVFS-ALB transduced human 293 cells contained a band at molecular weight approximately 80 KDa that specifically reacted with rabbit anti-RdCVF antibodies. This band was not detected in the cell culture medium from rAAV-GFP control vector transduced cells. The data suggest both rAAV-ALB-RdCVFS and rAAV-RdCVFS-ALB vectors mediated human short RdCVF and albumin fusion protein expression and secretion in human cells.

The rAAV-ALB-RdCVFS or rAAV-RdCVFS-ALB vectors can be used for intraocular administration to treat the diseases listed above. Specifically, the vectors can be delivered via subretinal injection or intravitreal injection.

Summary

The recombinant AAV vector encoding a codon-optimized (recoded) human short RdCVF fused with human albumin fusion protein coding sequence at its N-terminus was able to mediate the fusion protein expression in and secretion from human cells. The recombinant AAV vector encoding a codon-optimized human short RdCVF fused with human albumin fusion protein at its C-terminus was able to mediate the fusion protein expression in and secretion from human cells.

CLAIMS

1. A fusion protein comprising: (a) a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; or (b) a second peptide sequence and a third peptide sequence C-terminal to the second peptide sequence;
wherein the first peptide sequence is an Igk signal sequence, the second peptide sequence is an RdCVF-short sequence, and the third peptide sequence is a human albumin; and
wherein the fusion protein has the sequence (SEQ ID NO:3) or amino acids 22-732 of (SEQ ID NO:3).
2. A nucleic acid encoding the fusion protein of claim 1.
3. The nucleic acid of claim 2, encoding a fusion protein having the sequence (SEQ ID NO:3).
4. The nucleic acid of claim 3, having the sequence (SEQ ID NO:4).
5. An expression vector comprising the nucleic acid of claim 2 or 3, operatively linked to a control sequence.
6. The expression vector of claim 5, wherein the control sequence is a promoter.
7. The expression vector of claim 6, wherein the promoter is a CMV promoter.
8. The expression vector of claim 5, wherein the vector is a plasmid.
9. The expression vector of claim 8, wherein the vector is an AAV expression plasmid.

10. The expression vector of claim 5, wherein the vector is a viral vector.
11. The expression vector of claim 10, wherein the viral vector is selected from the group consisting of an AAV vector, a Lentiviral vector, a retroviral vector, an Adenoviral vector, and a synthetic viral vector.
12. A cell comprising the nucleic acid of any one of claims 2-4 or the expression vector of any one of claims 5-11.
13. A pharmaceutical composition comprising: (i) a component selected from the group consisting of the fusion protein of claim 1, the nucleic acid of any one of claims 2-4, the expression vector of any one of claims 5-11, or the cell of claim 12; and (ii) a pharmaceutically acceptable carrier.
14. A method of protecting ocular photoreceptor cells in a patient, comprising administering to the eye of the patient an effective amount of the fusion protein of claim 1, the nucleic acid of any one of claims 2-4, the expression vector of any one of claims 5-11, the cell of claim 12, or the pharmaceutical composition of claim 13, thereby protecting the ocular photoreceptor cells in the patient.
15. The method of claim 14, wherein the administration is selected from the group consisting of subretinal injection and intravitreal injection.
16. The method of claim 14 or claim 15, wherein the patient is a human patient.
17. The method of any one of claims 14-16, wherein the patient is a mammalian patient suffering from an ocular condition selected from the group consisting of retinal dystrophy, Stargardt's disease, retinitis pigmentosa, dry age-related macular degeneration (dry AMD), geographic atrophy (advanced stage of dry AMD), wet age-related macular degeneration (wet AMD), glaucoma with or without ocular hypertension, diabetic retinopathy, Bardet-Biedel syndrome, Bassen-Kornzweig syndrome, Best disease,

choroidema, gyrate atrophy, congenital amaurosis, refsum syndrome, Usher syndrome, thyroid related eye disease, Grave's disease, a disease associated with retinal pigmented epithelial cells, anterior segment disease, lens disease/cataracts, an eye cup disorder, and uveitis.

18. Use of the fusion protein of claim 1, the nucleic acid of any one of claims 2-4, the expression vector of any one of claims 5-11, the cell of claim 12, or the pharmaceutical composition of claim 13, in the manufacture of a medicament for protecting ocular photoreceptor cells in a patient.

19. The use of claim 18, wherein the patient is a mammalian patient suffering from an ocular condition selected from the group consisting of retinal dystrophy, Stargardt's disease, retinitis pigmentosa, dry age-related macular degeneration (dry AMD), geographic atrophy (advanced stage of dry AMD), wet age-related macular degeneration (wet AMD), glaucoma with or without ocular hypertension, diabetic retinopathy, Bardet-Biedel syndrome, Bassen-Kornzweig syndrome, Best disease, choroidema, gyrate atrophy, congenital amaurosis, refsum syndrome, Usher syndrome, thyroid related eye disease, Grave's disease, a disease associated with retinal pigmented epithelial cells, anterior segment disease, lens disease/cataracts, an eye cup disorder, and uveitis.

20. A method for producing a fusion protein of claim 1, comprising culturing the cell of claim 12,

wherein the cell comprises an expression vector, the expression vector comprises a nucleic acid encoding a fusion protein having the sequence (SEQ ID NO:3), and the nucleic acid is operatively linked to a control sequence,

under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.

M A S L F S G R I L I R N N S D Q D E L D T E A E V S R R L E N R
L V L L F F G A G A C P Q C Q A F V P I L K D F F V R L T D E F Y
V L R A A Q L A L V Y V S Q D S T E E Q Q D L F L K D M P K K W L
F L P F E D D L R R (SEQ ID NO: 5)

Figure 1A

M A S L F S G R I L I R N N S D Q D E L D T E A E V S R R L E N R
 L V L L F F G A G A C P Q C Q A F V P I L K D F F V R L T D E F Y
 V L R A A Q L A L V Y V S Q D S T E E Q Q D L F L K D M P K K W L
 F L P F E D D L R R D L G R Q F S V E R L P A V V V L K P D G D V
L T R D G A D E I Q R L G T A C F A N W Q E A A E V L D R N F Q L
 P E D L E D Q E P R S L T E C L R R H K Y R V E K A A R G G R D P
 G G G G G E E G G A G G L F (SEQ ID NO: 6)

Figure 1B




Figure 2




Figure 3

WOC-019PCT_SeqLi sting_20171010_ST25. txt
SEQUENCE LISTING

<110> Wellstat Ophthalmics Corporation
<120> Fusion Protein Between Short Form Rod-Derived Cone Viability Factor and a Hydrophilic Peptide
<130> WOC-019PCT
<150> US 62/406,552
<151> 2016-10-11
<160> 6
<170> PatentIn version 3.5
<210> 1
<211> 717
<212> PRT
<213> Homo sapiens

<220>
<221> SIGNAL
<222> (1)..(24)
<223> Signal sequence from human albumin

<220>
<221> MI SC_FEATURE
<222> (1)..(609)
<223> Human albumin (including N-terminal signal peptide)

<220>
<221> MI SC_FEATURE
<222> (25)..(609)
<223> Human albumin (excluding N-terminal signal peptide)

<220>
<221> MI SC_FEATURE
<222> (610)..(717)
<223> RdCVFS

<400> 1

Met Lys Trp Val Thr Phe Ile Ser Leu Leu Phe Leu Phe Ser Ser Ala
1 5 10 15

Tyr Ser Arg Gly Val Phe Arg Arg Asp Ala His Lys Ser Glu Val Ala
20 25 30

His Arg Phe Lys Asp Leu Gly Glu Glu Asn Phe Lys Ala Leu Val Leu
35 40 45

Ile Ala Phe Ala Gln Tyr Leu Gln Gln Cys Pro Phe Glu Asp His Val
50 55 60

Lys Leu Val Asn Glu Val Thr Glu Phe Ala Lys Thr Cys Val Ala Asp
65 70 75 80

Glu Ser Ala Glu Asn Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp
85 90 95

Lys Leu Cys Thr Val Ala Thr Leu Arg Glu Thr Tyr Gly Glu Met Ala
 100 105 110
 Asp Cys Cys Ala Lys Gln Glu Pro Glu Arg Asn Glu Cys Phe Leu Gln
 115 120 125
 His Lys Asp Asp Asn Pro Asn Leu Pro Arg Leu Val Arg Pro Glu Val
 130 135 140
 Asp Val Met Cys Thr Ala Phe His Asp Asn Glu Glu Thr Phe Leu Lys
 145 150 155 160
 Lys Tyr Leu Tyr Glu Ile Ala Arg Arg His Pro Tyr Phe Tyr Ala Pro
 165 170 175
 Glu Leu Leu Phe Phe Ala Lys Arg Tyr Lys Ala Ala Phe Thr Glu Cys
 180 185 190
 Cys Gln Ala Ala Asp Lys Ala Ala Cys Leu Leu Pro Lys Leu Asp Glu
 195 200 205
 Leu Arg Asp Glu Gly Lys Ala Ser Ser Ala Lys Gln Arg Leu Lys Cys
 210 215 220
 Ala Ser Leu Gln Lys Phe Gly Glu Arg Ala Phe Lys Ala Trp Ala Val
 225 230 235 240
 Ala Arg Leu Ser Gln Arg Phe Pro Lys Ala Glu Phe Ala Glu Val Ser
 245 250 255
 Lys Leu Val Thr Asp Leu Thr Lys Val His Thr Glu Cys Cys His Gly
 260 265 270
 Asp Leu Leu Glu Cys Ala Asp Asp Arg Ala Asp Leu Ala Lys Tyr Ile
 275 280 285
 Cys Glu Asn Gln Asp Ser Ile Ser Ser Lys Leu Lys Glu Cys Cys Glu
 290 295 300
 Lys Pro Leu Leu Glu Lys Ser His Cys Ile Ala Glu Val Glu Asn Asp
 305 310 315 320
 Glu Met Pro Ala Asp Leu Pro Ser Leu Ala Ala Asp Phe Val Glu Ser
 325 330 335
 Lys Asp Val Cys Lys Asn Tyr Ala Glu Ala Lys Asp Val Phe Leu Gly
 340 345 350
 Met Phe Leu Tyr Glu Tyr Ala Arg Arg His Pro Asp Tyr Ser Val Val
 355 360 365

Leu Leu Leu Arg Leu Ala Lys Thr Tyr Glu Thr Thr Leu Glu Lys Cys
 370 375 380
 Cys Ala Ala Ala Asp Pro His Glu Cys Tyr Ala Lys Val Phe Asp Glu
 385 390 395 400
 Phe Lys Pro Leu Val Glu Glu Pro Gln Asn Leu Ile Lys Gln Asn Cys
 405 410 415
 Glu Leu Phe Glu Gln Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu
 420 425 430
 Val Arg Tyr Thr Lys Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val
 435 440 445
 Glu Val Ser Arg Asn Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His
 450 455 460
 Pro Glu Ala Lys Arg Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val
 465 470 475 480
 Leu Asn Gln Leu Cys Val Leu His Glu Lys Thr Pro Val Ser Asp Arg
 485 490 495
 Val Thr Lys Cys Cys Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe
 500 505 510
 Ser Ala Leu Glu Val Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala
 515 520 525
 Glu Thr Phe Thr Phe His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu
 530 535 540
 Arg Gln Ile Lys Lys Gln Thr Ala Leu Val Glu Leu Val Lys His Lys
 545 550 555 560
 Pro Lys Ala Thr Lys Glu Gln Leu Lys Ala Val Met Asp Asp Phe Ala
 565 570 575
 Ala Phe Val Glu Lys Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe
 580 585 590
 Ala Glu Glu Gly Lys Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly
 595 600 605
 Leu Ala Ser Leu Phe Ser Gly Arg Ile Leu Ile Arg Asn Asn Ser Asp
 610 615 620
 Gln Asp Glu Leu Asp Thr Glu Ala Glu Val Ser Arg Arg Leu Glu Asn
 625 630 635 640

Arg Leu Val Leu Leu Phe Phe Gly Ala Gly Ala Cys Pro Gln Cys Gln
645 650 655

Ala Phe Val Pro Ile Leu Lys Asp Phe Phe Val Arg Leu Thr Asp Glu
660 665 670

Phe Tyr Val Leu Arg Ala Ala Gln Leu Ala Leu Val Tyr Val Ser Gln
675 680 685

Asp Ser Thr Glu Glu Gln Gln Asp Leu Phe Leu Lys Asp Met Pro Lys
690 695 700

Lys Trp Leu Phe Leu Pro Phe Glu Asp Asp Leu Arg Arg
705 710 715

<210> 2
<211> 2154
<212> DNA
<213> Homo sapiens

<400> 2
atgaagtggg taacctttat ttcccttctt tttctcttta gctcggctta ttccaggggt 60
gtgtttcgtc gagatgcaca caagagtgag gttgctcatc ggtttaaaga tttgggagaa 120
gaaaatttca aagccttggg gttgattgcc tttgctcagt atcttcagca gtgtccattt 180
gaagatcatg taaaattagt gaatgaagta actgaatttg caaaaacatg tgttgctgat 240
gagtcagctg aaaattgtga caaatcactt catacccttt ttggagacaa attatgcaca 300
gttgcaactc ttcgtgaaac ctatggtgaa atggctgact gctgtgcaaa acaagaacct 360
gagagaaatg aatgcttctt gcaacacaaa gatgacaacc caaacctccc ccgattgggtg 420
agaccagagg ttgatgtgat gtgcactgct tttcatgaca atgaagagac atttttgaaa 480
aaatacttat atgaaattgc cagaagacat cttactttt atgccccgga actccttttc 540
tttgctaaaa ggtataaagc tgcttttaca gaatgttgcc aagctgctga taaagctgcc 600
tgctgttgc caaagctcga tgaacttcgg gatgaaggga aggcttcgtc tgccaaacag 660
agactcaagt gtgccagtct ccaaaaattt ggagaaagag ctttcaaagc atgggcagta 720
gctcgcctga gccagagatt tcccaaagct gagtttcag aagtttccaa gttagtgaca 780
gatcttacca aagtccacac ggaatgctgc catggagatc tgcttgaatg tgctgatgac 840
agggcggacc ttgccaagta tatctgtgaa aatcaagatt cgatctccag taaactgaag 900
gaatgctgtg aaaaacctct gttggaaaaa tccactgca ttgccgaagt ggaaaatgat 960
gagatgcctg ctgacttgcc ttcattagct gctgattttg ttgaaagtaa ggatgtttgc 1020
aaaaactatg ctgaggcaaa ggatgtcttc ctgggcatgt ttttgtatga atatgcaaga 1080
aggcatcctg attactctgt cgtgctgctg ctgagacttg ccaagacata tgaaccact 1140
ctagagaagt gctgtgccgc tgcagatcct catgaatgct atgccaaagt gttcgatgaa 1200
tttaaacctc ttgtggaaga gcctcagaat ttaatcaaac aaaattgtga gctttttgag 1260

```

cagcttggag agtacaaatt ccagaatgcg ctattagttc gttacaccaa gaaagtaccc 1320
caagtgtcaa ctccaactct tgtagaggtc tcaagaaacc taggaaaagt gggcagcaaa 1380
tgttgtaaac atcctgaagc aaaaagaatg ccctgtgcag aagactatct atccgtggtc 1440
ctgaaccagt tatgtgtgtt gcatgagaaa acgccagtaa gtgacagagt caccaaatgc 1500
tgcacagaat ccttggtgaa caggcgacca tgcttttcag ctctggaagt cgatgaaaca 1560
tacgttccca aagagtttaa tgctgaaaca ttcaccttcc atgcagatat atgcacactt 1620
tctgagaagg agagacaaat caagaaacaa actgcacttg ttgagctcgt gaaacacaag 1680
cccaaggcaa caaaagagca actgaaagct gttatggatg atttcgcagc ttttgtagag 1740
aagtgtgca aggctgacga taaggagacc tgctttgccg aggagggtaa aaaacttggt 1800
gctgcaagtc aagctgcctt aggccttagcc agcctgttca gcggccggat cctgatcagg 1860
aacaacagcg accaggacga gctggacacc gaggccgaag tgagcaggag gctggagaac 1920
agactggtgc tgctgttctt tggcgccgga gcctgccctc agtgccaggc cttcgtgccc 1980
atcctgaagg atttctttgt gcggctgacc gacgagttct acgtgctgag agccgcccag 2040
ctggccctgg tgtatgtgag ccaggacagc accgaggagc agcaggacct gttcctgaag 2100
gacatgccca agaagtggct gttcctgccc ttcgaggacg acctgcggag atga 2154

```

```

<210> 3
<211> 732
<212> PRT
<213> Arti fi ci al Sequence

```

```

<220>
<223> N-terminal signal sequence from mouse IgK, followed by spacer,
followed by RdCVFS, followed by spacer, followed by human albumin
at C-terminus.

```

```

<220>
<221> SI GNAL
<222> (1)..(21)
<223> Signal sequence from mouse Igk.

```

```

<220>
<221> MI SC_FEATURE
<222> (22)..(35)
<223> Spacer

```

```

<220>
<221> MI SC_FEATURE
<222> (36)..(143)
<223> RdCVFS

```

```

<220>
<221> MI SC_FEATURE
<222> (144)..(147)
<223> Spacer

```

```

<220>
<221> MI SC_FEATURE
<222> (148)..(732)
<223> Human al bumin

```

```

<400> 3

```

WOC-019PCT_SeqLi sting_20171010_ST25. txt

Met Gl u Thr Asp Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro
1 5 10 15

Gly Ser Thr Gly Asp Ala Ala Gl n Pro Ala Arg Arg Ala Val Arg Ser
20 25 30

Leu Val Pro Ala Ser Leu Phe Ser Gly Arg Ile Leu Ile Arg Asn Asn
35 40 45

Ser Asp Gl n Asp Gl u Leu Asp Thr Gl u Ala Gl u Val Ser Arg Arg Leu
50 55 60

Gl u Asn Arg Leu Val Leu Leu Phe Phe Gly Ala Gly Ala Cys Pro Gl n
65 70 75 80

Cys Gl n Ala Phe Val Pro Ile Leu Lys Asp Phe Phe Val Arg Leu Thr
85 90 95

Asp Gl u Phe Tyr Val Leu Arg Ala Ala Gl n Leu Ala Leu Val Tyr Val
100 105 110

Ser Gl n Asp Ser Thr Gl u Gl u Gl n Gl n Asp Leu Phe Leu Lys Asp Met
115 120 125

Pro Lys Lys Trp Leu Phe Leu Pro Phe Gl u Asp Asp Leu Arg Arg Gly
130 135 140

Arg Asp Ala Asp Ala His Lys Ser Gl u Val Ala His Arg Phe Lys Asp
145 150 155 160

Leu Gly Gl u Gl u Asn Phe Lys Ala Leu Val Leu Ile Ala Phe Ala Gl n
165 170 175

Tyr Leu Gl n Gl n Cys Pro Phe Gl u Asp His Val Lys Leu Val Asn Gl u
180 185 190

Val Thr Gl u Phe Ala Lys Thr Cys Val Ala Asp Gl u Ser Ala Gl u Asn
195 200 205

Cys Asp Lys Ser Leu His Thr Leu Phe Gly Asp Lys Leu Cys Thr Val
210 215 220

Ala Thr Leu Arg Gl u Thr Tyr Gly Gl u Met Ala Asp Cys Cys Ala Lys
225 230 235 240

Gl n Gl u Pro Gl u Arg Asn Gl u Cys Phe Leu Gl n His Lys Asp Asp Asn
245 250 255

Pro Asn Leu Pro Arg Leu Val Arg Pro Gl u Val Asp Val Met Cys Thr
260 265 270

WOC-019PCT_SeqLi sting_20171010_ST25. txt

Al a Phe His Asp Asn Gl u Gl u Thr Phe Leu Lys Lys Tyr Leu Tyr Gl u
275 280 285

I l e Al a Arg Arg His Pro Tyr Phe Tyr Al a Pro Gl u Leu Leu Phe Phe
290 295 300

Al a Lys Arg Tyr Lys Al a Al a Phe Thr Gl u Cys Cys Gl n Al a Al a Asp
305 310 315 320

Lys Al a Al a Cys Leu Leu Pro Lys Leu Asp Gl u Leu Arg Asp Gl u Gl y
325 330 335

Lys Al a Ser Ser Al a Lys Gl n Arg Leu Lys Cys Al a Ser Leu Gl n Lys
340 345 350

Phe Gl y Gl u Arg Al a Phe Lys Al a Trp Al a Val Al a Arg Leu Ser Gl n
355 360 365

Arg Phe Pro Lys Al a Gl u Phe Al a Gl u Val Ser Lys Leu Val Thr Asp
370 375 380

Leu Thr Lys Val His Thr Gl u Cys Cys His Gl y Asp Leu Leu Gl u Cys
385 390 395 400

Al a Asp Asp Arg Al a Asp Leu Al a Lys Tyr I l e Cys Gl u Asn Gl n Asp
405 410 415

Ser I l e Ser Ser Lys Leu Lys Gl u Cys Cys Gl u Lys Pro Leu Leu Gl u
420 425 430

Lys Ser His Cys I l e Al a Gl u Val Gl u Asn Asp Gl u Met Pro Al a Asp
435 440 445

Leu Pro Ser Leu Al a Al a Asp Phe Val Gl u Ser Lys Asp Val Cys Lys
450 455 460

Asn Tyr Al a Gl u Al a Lys Asp Val Phe Leu Gl y Met Phe Leu Tyr Gl u
465 470 475 480

Tyr Al a Arg Arg His Pro Asp Tyr Ser Val Val Leu Leu Leu Arg Leu
485 490 495

Al a Lys Thr Tyr Gl u Thr Thr Leu Gl u Lys Cys Cys Al a Al a Al a Asp
500 505 510

Pro His Gl u Cys Tyr Al a Lys Val Phe Asp Gl u Phe Lys Pro Leu Val
515 520 525

Gl u Gl u Pro Gl n Asn Leu I l e Lys Gl n Asn Cys Gl u Leu Phe Gl u Gl n
530 535 540

Leu Gly Glu Tyr Lys Phe Gln Asn Ala Leu Leu Val Arg Tyr Thr Lys
545 550 555 560

Lys Val Pro Gln Val Ser Thr Pro Thr Leu Val Glu Val Ser Arg Asn
565 570 575

Leu Gly Lys Val Gly Ser Lys Cys Cys Lys His Pro Glu Ala Lys Arg
580 585 590

Met Pro Cys Ala Glu Asp Tyr Leu Ser Val Val Leu Asn Gln Leu Cys
595 600 605

Val Leu His Glu Lys Thr Pro Val Ser Asp Arg Val Thr Lys Cys Cys
610 615 620

Thr Glu Ser Leu Val Asn Arg Arg Pro Cys Phe Ser Ala Leu Glu Val
625 630 635 640

Asp Glu Thr Tyr Val Pro Lys Glu Phe Asn Ala Glu Thr Phe Thr Phe
645 650 655

His Ala Asp Ile Cys Thr Leu Ser Glu Lys Glu Arg Gln Ile Lys Lys
660 665 670

Gln Thr Ala Leu Val Glu Leu Val Lys His Lys Pro Lys Ala Thr Lys
675 680 685

Glu Gln Leu Lys Ala Val Met Asp Asp Phe Ala Ala Phe Val Glu Lys
690 695 700

Cys Cys Lys Ala Asp Asp Lys Glu Thr Cys Phe Ala Glu Glu Gly Lys
705 710 715 720

Lys Leu Val Ala Ala Ser Gln Ala Ala Leu Gly Leu
725 730

<210> 4
<211> 2199
<212> DNA
<213> Arti f i c i a l Sequence

<220>
<223> N-terminal signal sequence from mouse IgK, followed by spacer,
followed by RdCVFS, followed by spacer, followed by human albumin
at C-terminus.

<400> 4
atggagacag acacactcct gctatgggta ctgctgctct gggttccagg ttccactggt 60
gacgcggccc agccggccag gcgcgccgta cgaagcttgg taccgcccag cctgttcagc 120
ggccggatcc tgatcaggaa caacagcgac caggacgagc tggacaccga ggccgaagtg 180
agcaggaggc tggagaacag actggtgctg ctgttctttg gcgccggagc ctgccctcag 240

tgccaggcct tcgtgccc	cctgaaggat ttctttgtgc	ggctgaccga cgagttctac	300		
gtgctgagag ccgcccagct	ggccctggtg tatgtgagcc	aggacagcac cgaggagcag	360		
caggacctgt tcctgaagga	catgcccaag aagtggctgt	tcctgccctt cgaggacgac	420		
ctgcggagag gacgagatgc	agatgcacac aagagtgagg	ttgctcatcg gtttaaagat	480		
ttgggagaag aaaatttcaa	agccttggtg ttgattgcct	ttgctcagta tcttcagcag	540		
tgtccatttg aagatcatgt	aaaattagtg aatgaagtaa	ctgaatttgc aaaaacatgt	600		
gttgctgatg agtcagctga	aaattgtgac aaatcacttc	ataccctttt tggagacaaa	660		
ttatgcacag ttgcaactct	tcgtgaaacc tatggtgaaa	tggctgactg ctgtgcaaaa	720		
caagaacctg agagaaatga	atgcttcttg caacacaaag	atgacaaccc aaacctcccc	780		
cgattggtga gaccagaggt	tgatgtgatg tgcactgctt	ttcatgacaa tgaagagaca	840		
tttttgaaaa aatacttata	tgaaattgcc agaagacatc	cttactttta tgccccggaa	900		
ctccttttct ttgctaaaag	gtataaagct gcttttacag	aatgttgcca agctgctgat	960		
aaagctgcct gcctgttgcc	aaagctcgat gaacttcggg	atgaagggaa ggcttcgtct	1020		
gccaaacaga gactcaagtg	tgccagtctc caaaaatttg	gagaaagagc tttcaaagca	1080		
tgggcagtag ctgcctgag	ccagagattt cccaaagctg	agtttgcaga agtttccaag	1140		
ttagtgacag atcttaccaa	agtccacacg gaatgctgcc	atggagatct gcttgaatgt	1200		
gctgatgaca gggcggacct	tgccaagtat atctgtgaaa	atcaagattc gatctccagt	1260		
aaactgaagg aatgctgtga	aaaacctctg ttggaaaaat	cccactgcat tgccgaagtg	1320		
gaaaatgatg agatgcctgc	tgacttgccct tcattagctg	ctgattttgt tgaaagtaag	1380		
gatgtttgca aaaactatgc	tgaggcaaag gatgtcttcc	tgggcatgtt tttgtatgaa	1440		
tatgcaagaa ggcacacctg	ttactctgtc gtgctgctgc	tgagacttgc caagacatat	1500		
gaaaccactc tagagaagtg	ctgtgccgct gcagatcctc	atgaatgcta tgccaaagtg	1560		
ttcgatgaat ttaaacctct	tgtggaagag cctcagaatt	taatcaaaca aaattgtgag	1620		
ctttttgagc agcttgagag	gtacaaattc cagaatgcgc	tattagtctg ttacaccaag	1680		
aaagtacccc aagtgtcaac	tccaactctt gtagaggtct	caagaaacct aggaaaagtg	1740		
ggcagcaa	aat gttgtaaaca	tcctgaagca aaaagaatgc	cctgtgcaga agactatcta	1800	
tccgtggtcc tgaaccagtt	atgtgtgttg catgagaaaa	cgccagtaag tgacagagtc	1860		
accaa	atgct gcacagaatc	cttggtgaac aggcgacat	gcttttcagc tctggaagtc	1920	
gatgaa	acat acgttcccaa	agagttta	gctgaaacat tcaccttcca	tgcagatata	1980
tgcacacttt ctgagaagga	gagacaaatc aagaaacaaa	ctgcacttgt tgagctcgtg	2040		
aaacacaagc ccaaggcaac	aaaagagcaa ctgaaagctg	ttatggatga tttcgcagct	2100		
ttttagaga agtgctgcaa	ggctgacgat aaggagacct	gctttgccga ggagggtaaa	2160		
aaacttg	ttg ctgcaagtca	agctgcctta ggcttataa	2199		

<211> 109
 <212> PRT
 <213> Homo sapiens
 <400> 5

Met Ala Ser Leu Phe Ser Gly Arg Ile Leu Ile Arg Asn Asn Ser Asp
 1 5 10 15

Gln Asp Glu Leu Asp Thr Glu Ala Glu Val Ser Arg Arg Leu Glu Asn
 20 25 30

Arg Leu Val Leu Leu Phe Phe Gly Ala Gly Ala Cys Pro Gln Cys Gln
 35 40 45

Ala Phe Val Pro Ile Leu Lys Asp Phe Phe Val Arg Leu Thr Asp Glu
 50 55 60

Phe Tyr Val Leu Arg Ala Ala Gln Leu Ala Leu Val Tyr Val Ser Gln
 65 70 75 80

Asp Ser Thr Glu Glu Gln Gln Asp Leu Phe Leu Lys Asp Met Pro Lys
 85 90 95

Lys Trp Leu Phe Leu Pro Phe Glu Asp Asp Leu Arg Arg
 100 105

<210> 6
 <211> 212
 <212> PRT
 <213> Homo sapiens
 <400> 6

Met Ala Ser Leu Phe Ser Gly Arg Ile Leu Ile Arg Asn Asn Ser Asp
 1 5 10 15

Gln Asp Glu Leu Asp Thr Glu Ala Glu Val Ser Arg Arg Leu Glu Asn
 20 25 30

Arg Leu Val Leu Leu Phe Phe Gly Ala Gly Ala Cys Pro Gln Cys Gln
 35 40 45

Ala Phe Val Pro Ile Leu Lys Asp Phe Phe Val Arg Leu Thr Asp Glu
 50 55 60

Phe Tyr Val Leu Arg Ala Ala Gln Leu Ala Leu Val Tyr Val Ser Gln
 65 70 75 80

Asp Ser Thr Glu Glu Gln Gln Asp Leu Phe Leu Lys Asp Met Pro Lys
 85 90 95

Lys Trp Leu Phe Leu Pro Phe Glu Asp Asp Leu Arg Arg Asp Leu Gly
 100 105 110

WOC-019PCT_SeqLi sting_20171010_ST25. txt

Arg Gln Phe Ser Val Glu Arg Leu Pro Ala Val Val Val Leu Lys Pro
115 120 125

Asp Gly Asp Val Leu Thr Arg Asp Gly Ala Asp Glu Ile Gln Arg Leu
130 135 140

Gly Thr Ala Cys Phe Ala Asn Trp Gln Glu Ala Ala Glu Val Leu Asp
145 150 155 160

Arg Asn Phe Gln Leu Pro Glu Asp Leu Glu Asp Gln Glu Pro Arg Ser
165 170 175

Leu Thr Glu Cys Leu Arg Arg His Lys Tyr Arg Val Glu Lys Ala Ala
180 185 190

Arg Gly Gly Arg Asp Pro Gly Gly Gly Gly Gly Glu Glu Gly Gly Ala
195 200 205

Gly Gly Leu Phe
210